Equities

Allergy Therapeutics PLC

AGY:LSE

Allergy Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)2.90
  • Today's Change0.025 / 0.87%
  • Shares traded10.69k
  • 1 Year change--
  • Beta1.9646
Data delayed at least 20 minutes, as of May 02 2024 10:05 BST.
More ▼

Profile data is unavailable for this security.

About the company

Allergy Therapeutics plc is a United Kingdom-based integrated specialty pharmaceutical company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.

  • Revenue in GBP (TTM)53.26m
  • Net income in GBP-50.22m
  • Incorporated2004
  • Employees635.00
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Eco Animal Health Group Plc88.46m-1.62m75.70m228.0075.70m228.00
Scancell Holdings Plc0.00-11.32m85.84m51.0085.84m51.00
Futura Medical PLC3.10m-6.51m99.18m12.0099.18m12.00
Faron Pharmaceuticals Oy0.00-26.46m108.15m34.00108.15m34.00
Allergy Therapeutics plc53.26m-50.22m137.04m635.00137.04m635.00
4Basebio PLC354.00k-6.28m137.66m--137.66m--
Animalcare Group Plc74.35m1.20m141.85m220.00141.85m220.00
Avacta Group Plc16.03m-42.08m167.85m120.00167.85m120.00
Alliance Pharma plc170.05m-7.06m183.74m249.00183.74m249.00
hVIVO PLC56.04m16.12m189.14m274.00189.14m274.00
Data as of May 02 2024. Currency figures normalised to Allergy Therapeutics PLC's reporting currency: UK Pound GBX

Institutional shareholders

3.90%Per cent of shares held by top holders
HolderShares% Held
JPMorgan Chase Bank, NA (Investment Management)as of 01 Mar 2024124.00m2.60%
Hargreaves Lansdown Asset Management Ltd.as of 01 Mar 202416.00m0.34%
West Yorkshire Pension Fundas of 01 Mar 202413.88m0.29%
Panmure Gordon (UK) Ltd.as of 01 Mar 202410.22m0.21%
IG Markets Ltd.as of 01 Mar 20248.95m0.19%
HSBC Global Asset Management (UK) Ltd.as of 01 Mar 20244.69m0.10%
Santander Asset Management SA SGIICas of 01 Mar 20243.13m0.07%
Raiffeisen Kapitalanlage-Gesellschaft mbHas of 01 Mar 20242.03m0.04%
iDealing.com Ltd.as of 01 Mar 20241.42m0.03%
Bank Julius B�r & Co. AGas of 01 Mar 20241.39m0.03%
More ▼
Data from 31 Mar 2023 - 02 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.